Maintenance Infliximab Treatment Is Associated with Improved Bone Mineral Density in Crohn's Disease (Q22242347)

From Wikidata

Jump to navigation Jump to search

scientific article

Maintenance infliximab treatment is associated with improved bone mineral density in Crohn's disease

Language	Label	Description	Also known as
English	Maintenance Infliximab Treatment Is Associated with Improved Bone Mineral Density in Crohn's Disease	scientific article	Maintenance infliximab treatment is associated with improved bone mineral density in Crohn's disease

Statements

scholarly article

0 references

Maintenance Infliximab Treatment Is Associated with Improved Bone Mineral Density in Crohn's Disease (English)

0 references

Crohn's disease

0 references

author name string

Michael Bernstein

1

author given names

Michael

author last names

Bernstein

1 reference

PubMed publication ID

28 March 2023

Sue Irwin

2

author given names

Sue

author last names

Irwin

1 reference

PubMed publication ID

28 March 2023

Gordon R. Greenberg

3

author given names

Gordon R

author last names

Greenberg

1 reference

PubMed publication ID

28 March 2023

language of work or name

0 references

publication date

September 2005

0 references

The American Journal of Gastroenterology

0 references

100

0 references

9

0 references

2031-2035

0 references

Bone loss. Factors that regulate osteoclast differentiation: an update

1 reference

https://api.crossref.org/works/10.1111/J.1572-0241.2005.50219.X

20 April 2017

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

1 reference

https://api.crossref.org/works/10.1111/J.1572-0241.2005.50219.X

20 April 2017

Infliximab maintenance therapy for fistulizing Crohn's disease

1 reference

https://api.crossref.org/works/10.1111/J.1572-0241.2005.50219.X

20 April 2017

RANK-L and RANK: T cells, bone loss, and mammalian evolution

1 reference

https://api.crossref.org/works/10.1111/J.1572-0241.2005.50219.X

20 April 2017

Evaluation of bone mineral density in inflammatory bowel disease: current safety focus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.50219.X

21 January 2018

Glucocorticoid osteoporosis--mechanisms and management

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.50219.X

21 January 2018

Fracture risk is increased in Crohn's disease, but not in ulcerative colitis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.50219.X

21 January 2018

The association between corticosteroid use and development of fractures among IBD patients in a population-based database

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.50219.X

21 January 2018

Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.50219.X

21 January 2018

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.50219.X

21 January 2018

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.50219.X

21 January 2018

Bone mineral density in Crohn's disease: a longitudinal study of budesonide, prednisone, and nonsteroid therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.50219.X

21 January 2018

CD4+CD45RBHi T cell transfer induced colitis in mice is accompanied by osteopenia which is treatable with recombinant human osteoprotegerin

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.50219.X

21 January 2018

Increase in bone mineral density of patients with spondyloarthropathy treated with anti-tumour necrosis factor alpha.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.50219.X

21 January 2018

Expression of the osteoblast differentiation factor RUNX2 (Cbfa1/AML3/Pebp2alpha A) is inhibited by tumor necrosis factor-alpha

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.50219.X

21 January 2018

Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.50219.X

21 January 2018

Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.50219.X

21 January 2018

A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.50219.X

21 January 2018

Randomized trial of etidronate plus calcium and vitamin D for treatment of low bone mineral density in Crohn's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.50219.X

21 January 2018

Bones and Crohnʼs

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.50219.X

21 January 2018

Identifiers

10.1111/J.1572-0241.2005.50219.X

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q22242347&oldid=1863375870"